Insider Selling: Alkermes Plc COO Sells 1,100 Shares of Stock (ALKS)
Alkermes Plc (NASDAQ:ALKS) COO Gordon G. Pugh sold 1,100 shares of Alkermes Plc stock on the open market in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $45.08, for a total value of $49,588.00. Following the completion of the sale, the chief operating officer now directly owns 32,527 shares of the company’s stock, valued at approximately $1,466,317. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Alkermes Plc (NASDAQ:ALKS) traded down 2.70% on Thursday, hitting $42.81. 1,044,632 shares of the company’s stock traded hands. Alkermes Plc has a 52 week low of $29.36 and a 52 week high of $54.25. The stock’s 50-day moving average is $43.97 and its 200-day moving average is $46.12. The company’s market cap is $6.243 billion.
Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.11 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter last year, the company posted $0.30 earnings per share. Alkermes Plc’s revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Alkermes Plc will post $0.27 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ALKS shares. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Wednesday, August 6th. They now have a $45.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday, August 1st. Finally, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Alkermes Plc currently has a consensus rating of “Buy” and a consensus target price of $48.50.
Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.